Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Treatment with 177Lu-FAPI-2286 and Chemotherapy in Breast Cancer
IRCT20250429065516N1Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of AAA614 in triple-negative breast cancer (TNBC), breast cancer and triple-positive breast cancer (TPBC), sponsored by Shahid Beheshti University of Medical Sciences. Started May 2025; status: recruiting.
02
Drugs
AAA614
03
Conditions
triple-negative breast cancer (TNBC)breast cancertriple-positive breast cancer (TPBC)
Beyond the preview
Go deeper on IRCT20250429065516N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250429065516N1.